{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:11:41Z","timestamp":1789690301893,"version":"4.0.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","award":["10014"],"award-info":[{"award-number":["10014"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The prognosis of malignant primary high-grade brain tumors, predominantly glioblastomas, is poor despite intensive multimodality treatment options. In more than 50% of patients with glioblastomas, potentially targetable mutations are present, including rearrangements, altered splicing, and\/or focal amplifications of epidermal growth factor receptor (EGFR) by signaling through the RAF\/RAS pathway. We studied whether treatment with the clinically available anti-EGFR monoclonal antibody panitumumab provides clinical benefit for patients with RAF\/RAS-wild-type (wt) glioblastomas in the Drug Rediscovery Protocol (DRUP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with progression of treatment refractory RAF\/RASwt glioblastoma were included for treatment with panitumumab in DRUP when measurable according to RANO criteria. The primary endpoints of this study are clinical benefit (CB: defined as confirmed objective response [OR] or stable disease [SD] \u2265 16 weeks) and safety. Patients were enrolled using a Simon-like 2-stage model, with 8 patients in stage 1 and up to 24 patients in stage 2 if at least 1 in 8 patients had CB in stage 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 03-2018 and 02-2022, 24 evaluable patients were treated. CB was observed in 5 patients (21%), including 2 patients with partial response (8.3%) and 3 patients with SD \u2265 16 weeks (12.5%). After median follow-up of 15 months, median progression-free survival and overall survival were 1.7 months (95% CI 1.6-2.1 months) and 4.5 months (95% CI 2.9-8.6 months), respectively. No unexpected toxicities were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Panitumumab treatment provides limited CB in patients with recurrent RAF\/RASwt glioblastoma precluding further development of this therapeutic strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad320","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:20:20Z","timestamp":1702923620000},"page":"431-440","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Panitumumab in Patients With <i>RAF<\/i>\/<i>RAS<\/i>-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9827-1138","authenticated-orcid":false,"given":"Ilse A C","family":"Spiekman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute , Erasmus MC, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit S","family":"Geurts","sequence":"additional","affiliation":[{"name":"Oncode Institute , Utrecht , The Netherlands"},{"name":"Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurien J","family":"Zeverijn","sequence":"additional","affiliation":[{"name":"Oncode Institute , Utrecht , The Netherlands"},{"name":"Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs F","family":"de Wit","sequence":"additional","affiliation":[{"name":"Oncode Institute , Utrecht , The Netherlands"},{"name":"Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-4535","authenticated-orcid":false,"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-0258","authenticated-orcid":false,"given":"Paul","family":"Roepman","sequence":"additional","affiliation":[{"name":"Hartwig Medical Foundation , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-6018","authenticated-orcid":false,"given":"Wendy W J","family":"de Leng","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Cancer Center Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-0563","authenticated-orcid":false,"given":"Anne M L","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Cancer Center Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Kusters","sequence":"additional","affiliation":[{"name":"Department of Pathology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-4626","authenticated-orcid":false,"given":"Laurens V","family":"Beerepoot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis) , Tilburg , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-5991","authenticated-orcid":false,"given":"Filip Y F L","family":"de Vos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-6835","authenticated-orcid":false,"given":"Derk-Jan A","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-5011","authenticated-orcid":false,"given":"Jan Willem B","family":"de Groot","sequence":"additional","affiliation":[{"name":"Isala Oncology Center , Isala, Zwolle , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0155-3005","authenticated-orcid":false,"given":"Ann","family":"Hoeben","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+ , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2929-1070","authenticated-orcid":false,"given":"Jan","family":"Buter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam University Medical Center , Location VuMC, Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans A J","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-9586","authenticated-orcid":false,"given":"Emile E","family":"Voest","sequence":"additional","affiliation":[{"name":"Oncode Institute , Utrecht , The Netherlands"},{"name":"Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"},{"name":"Center for Personalized Cancer Treatment , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M W","family":"Verheul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute , Erasmus MC, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"2024050313124863600_CIT0001","volume-title":"Glioomzorg in Nederland","author":"Registry DBT","year":"2019"},{"issue":"10","key":"2024050313124863600_CIT0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Roger","year":"2005","journal-title":"New England J Med"},{"key":"2024050313124863600_CIT0003","first-page":"ii1","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume-title":"Neuro Oncol","author":"Ostrom","year":"2013"},{"key":"2024050313124863600_CIT0004","first-page":"389","article-title":"Therapeutic options in recurrent glioblastoma--an update","volume-title":"Crit Rev Oncol Hematol","author":"Seystahl","year":"2016"},{"key":"2024050313124863600_CIT0005","first-page":"4733","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume-title":"J Clin Oncol","author":"Friedman","year":"2009"},{"key":"2024050313124863600_CIT0006","first-page":"740","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume-title":"J Clin Oncol","author":"Kreisl","year":"2009"},{"key":"2024050313124863600_CIT0007","first-page":"1954","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume-title":"N Engl J Med","author":"Wick","year":"2017"},{"key":"2024050313124863600_CIT0008","first-page":"183","article-title":"Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis","volume-title":"J Neurooncol","author":"van Linde","year":"2017"},{"key":"2024050313124863600_CIT0009","first-page":"574","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume-title":"JAMA","author":"Schaff","year":"2023"},{"key":"2024050313124863600_CIT0010","first-page":"105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume-title":"Pharmacol Res","author":"Wu","year":"2021"},{"key":"2024050313124863600_CIT0011","first-page":"803","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume-title":"Acta Neuropathol","author":"Louis","year":"2016"},{"issue":"7216","key":"2024050313124863600_CIT0012","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"2024050313124863600_CIT0013","first-page":"462","article-title":"The somatic genomic landscape of glioblastoma","volume-title":"Cell","author":"Brennan","year":"2013"},{"issue":"18 Suppl","key":"2024050313124863600_CIT0014","first-page":"32S","article-title":"The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia","volume":"19","author":"Arteaga","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024050313124863600_CIT0015","first-page":"748","article-title":"The EGFRvIII variant in glioblastoma multiforme","volume-title":"J Clin Neurosci","author":"Gan","year":"2009"},{"key":"2024050313124863600_CIT0016","first-page":"663","article-title":"Targeting the ERBB family in cancer: couples therapy","volume-title":"Nat Rev Cancer","author":"Tebbutt","year":"2013"},{"key":"2024050313124863600_CIT0017","first-page":"508","article-title":"Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial","volume-title":"Neuro Oncol","author":"Hasselbalch","year":"2010"},{"key":"2024050313124863600_CIT0018","first-page":"1596","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume-title":"Ann Oncol","author":"Neyns","year":"2009"},{"key":"2024050313124863600_CIT0019","first-page":"522","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume-title":"Eur J Cancer","author":"Westphal","year":"2015"},{"key":"2024050313124863600_CIT0020","first-page":"1803","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume-title":"J Clin Oncol","author":"Chung","year":"2005"},{"key":"2024050313124863600_CIT0021","first-page":"684","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume-title":"Neuro Oncol","author":"Van Den Bent","year":"2020"},{"key":"2024050313124863600_CIT0022","volume-title":"Full Prescribing Information","author":"Vectibix (panitumumab)","year":"2017"},{"key":"2024050313124863600_CIT0023","first-page":"127","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume-title":"Nature","author":"van der Velden","year":"2019"},{"key":"2024050313124863600_CIT0024","first-page":"1231","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume-title":"Neuro Oncol","author":"Louis","year":"2021"},{"key":"2024050313124863600_CIT0025","first-page":"2439","article-title":"Response assessment in neuro-oncology clinical trials","volume-title":"J Clin Oncol","author":"Wen","year":"2017"},{"key":"2024050313124863600_CIT0026","first-page":"561","article-title":"Admissible two-stage designs for phase II cancer clinical trials","volume-title":"Stat Med","author":"Jung","year":"2004"},{"key":"2024050313124863600_CIT0027","first-page":"179","article-title":"Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015","volume-title":"J Clin Oncol","author":"Allegra","year":"2016"},{"key":"2024050313124863600_CIT0028","first-page":"133","article-title":"Phase II trial of gefitinib in recurrent glioblastoma","volume-title":"J Clin Oncol","author":"Rich","year":"2004"},{"key":"2024050313124863600_CIT0029","first-page":"1268","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034","volume-title":"J Clin Oncol","author":"van den Bent","year":"2009"},{"key":"2024050313124863600_CIT0030","first-page":"1561","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume-title":"Oncogene","author":"An","year":"2018"},{"key":"2024050313124863600_CIT0031","first-page":"2012","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume-title":"N Engl J Med","author":"Mellinghoff","year":"2005"},{"key":"2024050313124863600_CIT0032","first-page":"e25046","article-title":"Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports","volume-title":"Medicine (Baltim)","author":"Lai","year":"2021"},{"key":"2024050313124863600_CIT0033","first-page":"537","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume-title":"Nature","author":"Diaz","year":"2012"},{"key":"2024050313124863600_CIT0034","first-page":"534","article-title":"De-repression of PDGFR\u03b2 transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients","volume-title":"Cancer Discov","author":"Akhavan","year":"2013"},{"key":"2024050313124863600_CIT0035","first-page":"287","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume-title":"Science","author":"Stommel","year":"2007"},{"key":"2024050313124863600_CIT0036","first-page":"1039","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume-title":"Science","author":"Engelman","year":"2007"},{"key":"2024050313124863600_CIT0037","first-page":"81","article-title":"Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study","volume-title":"J Clin Oncol","author":"Draaisma","year":"2020"},{"key":"2024050313124863600_CIT0038","first-page":"318","article-title":"Spatiotemporal evolution of the primary glioblastoma genome","volume-title":"Cancer Cell","author":"Kim","year":"2015"},{"key":"2024050313124863600_CIT0039","first-page":"768","article-title":"Clonal evolution of glioblastoma under therapy","volume-title":"Nat Genet","author":"Wang","year":"2016"},{"key":"2024050313124863600_CIT0040","first-page":"1595","article-title":"Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly diagnosed glioblastoma","volume-title":"Clin Cancer Res","author":"van Linde","year":"2022"},{"key":"2024050313124863600_CIT0041","first-page":"5705","article-title":"Macromolecular permeability across the blood-nerve and blood-brain barriers","volume-title":"Proc Natl Acad Sci USA","author":"Poduslo","year":"1994"},{"key":"2024050313124863600_CIT0042","first-page":"617","article-title":"A distinct advantage to intraarterial delivery of (89)Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier","volume-title":"J Nucl Med","author":"Lesniak","year":"2019"},{"key":"2024050313124863600_CIT0043","first-page":"vdab102","article-title":"Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin","volume-title":"Neurooncol Adv","author":"Gan","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/431\/57396383\/oyad320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/431\/57396383\/oyad320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:13:33Z","timestamp":1714742013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/5\/431\/7477512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,18]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad320","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,12,18]]}}}